Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Date:12/11/2012

redict", "intend" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

Note: Data in this release correspond to ASH Abstract 904.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
6. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
9. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
10. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
(Date:7/3/2015)... 2015 According to a ... Rhythm Management Market ECG, Implantable Loop Recorder, Manual ... Defibrillator, Dual Chamber Pacemaker, CRT-D, CRT-P - Global ... Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) ... by 2020 from $21,137.7 Million in 2015, at ...
(Date:7/3/2015)... July 3, 2015  Obsidian HDS, the developer of ... service for the management of data on pharmaceutical and ... PharmaShine now includes the 2014 Open Payments General and ... on June 30. The data disclosed on Open Payments ... industry and providers totaling $6.49 billion and is the ...
Breaking Medicine Technology:Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... CVS Caremark Corporation (NYSE: CVS ) ... 3, 2011, at 8:30 a.m. (ET) with analysts and ... as well as its initial guidance for 2011. ... the conference call will be broadcast simultaneously through the ...
... the stethoscope for the 21st century. Ultrasound is ... patients quickly and accurately. It,s been around for decades, but ... years, making the machines smaller, cheaper and smarter. ... making its own mark with ultrasound. It,s the only medical ...
Cached Medicine Technology:U of South Carolina, a Leader in Ultrasound Education, Hosts World Congress in Spring 2U of South Carolina, a Leader in Ultrasound Education, Hosts World Congress in Spring 3
(Date:7/2/2015)... ... ... Many Fourth of July celebrations will include fireworks this summer, so it’s ... some tips to promote the proper use of fireworks. , According to the U.S. ... with fireworks-related injuries in the month surrounding the Fourth of July. Amica is sharing ...
(Date:7/2/2015)... ... July 02, 2015 , ... In 2012, Patrick Achebe realized that the gift of poetry ... sat down to write his first poem, and three years later he was publishing an ... and worth sharing with the world. "I have always believed that the best way to ...
(Date:7/2/2015)... , ... July 02, 2015 , ... As Americans celebrate ... the hot temps, skin cancer is on the rise. July is UV Safety Month, ... raising awareness about the importance of getting skin checks. Experts say most skin cancers ...
(Date:7/2/2015)... CITY, GA (PRWEB) , ... July 02, 2015 , ... ... their newest innovation in compression socks designed for men. , For style that’s ... socks into their daily routine. This is great news for men everywhere because a ...
(Date:7/2/2015)... ... 02, 2015 , ... The ZAC Foundation, a national leader in water safety ... on how to stay water safe with the help of a young polar bear ... ZAC Foundation co-founders, follows Zeke’s water safety journey. Zeke, who is afraid of ...
Breaking Medicine News(10 mins):Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 2Health News:SIGVARIS Kicks Up Its Style for Men with the Launch of MIDTOWN MICROFIBER in a Dark Navy Stripe Pattern 3Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3
... transient neurological attacks, such as temporary amnesia or ... and dementia, according to a study in the ... neurological attacks (TNAs) are episodes involving temporary (less ... be nonfocal (that can include nonlocalizing cerebral symptoms), ...
... Early practice for youngsters can reduce risk of shoulder ... News) -- Playing catch with your young pitcher months before ... pitfall: torn rotator cuff injuries, according to doctors at Methodist ... - a high pitch count and throwing curve balls -- ...
... are among those that pose a threat, experts warn ... lead in toys has attracted a great deal of attention ... may pose to children. For example, some toys can damage ... There were more than 210,000 toy-related injuries treated in U.S. ...
... today announced that it has received a letter from ... bid price of the Company,s common,stock has closed below ... Marketplace Rule 4310(c)(4) (the "Rule").,Therefore, in accordance with Marketplace ... calendar days, or until June 16, 2008 to regain,compliance. ...
... 24 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: CHDX ... and products in the People,s Republic of China, ... the listing of its common stock on,the NASDAQ ... NASDAQ Capital,Market to the NASDAQ Global Market has ...
... PALM BEACH, Fla., Dec. 24 Veterans Affairs Medical,Center ... that could help reduce,the spiraling cost of healthcare nationwide., ... the area to adopt a privacy,curtain for hospital beds ... less maintenance than conventional hospital bed curtains. The,innovation called ...
Cached Medicine News:Health News:Some types of temporary neurological problems associated with increased risk for stroke, dementia 2Health News:Some types of temporary neurological problems associated with increased risk for stroke, dementia 3Health News:Playing Catch in Winter Could Save Kids' Pitching Arms 2Health News:Beware Holiday Toys That Can Injure Young Eyes 2Health News:QMed, Inc. Receives NASDAQ Letter 2Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 2Health News:Chindex International, Inc. Announces Transfer to NASDAQ Global Market 3Health News:VA Hospital Draws Curtain on Innovation That Could Help Reduce Spiraling Cost of Hospital Maintenance Nationwide 2
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
... ToRCH Plus Control is a ... monitor the performance of the ... and assays. A weak positive ... you to monitor the performance ...
Liquichek™ Ethanol/Ammonia Control is a liquid product used to monitor ethanol and ammonia test procedures in the clinical laboratory....
Liquid Assayed and Unassayed Multiqual Controls are comprehensive, liquid, human serum based chemistry controls, available in three levels....
Medicine Products: